

## Boehringer Ingelheim GmbH - Strategic SWOT Analysis Review

URL:	<a href="https://marketpublishers.com/r/BFFC7371C30EN.html">https://marketpublishers.com/r/BFFC7371C30EN.html</a>
Date:	May 2, 2017
Pages:	48
Price:	US\$ 125.00
ID:	BFFC7371C30EN

Boehringer Ingelheim GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

### Scope

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – GlobalData's summarization of the company's business strategy.
- SWOT analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.

### Highlights

Boehringer Ingelheim GmbH (Boehringer), a subsidiary of C. H. Boehringer Sohn AG & Co KG is a pharmaceutical company, which carries out research, development, manufacture and sale of pharmaceuticals. The company offers a wide range of products including prescription medicines, consumer health care products, animal health care products and biopharmaceuticals. Its products are used in the treatment of central nervous system disorders, respiratory diseases, cardiovascular diseases, metabolic disorders, cancer, urological and viral conditions, among others. The company focuses on the research, development, manufacture and marketing of new drugs of therapeutic value for human and veterinary medicine. Boehringer operates globally through affiliates and is headquartered in Ingelheim am Rhein, Rheinland-Pfalz, Germany.

### Boehringer Ingelheim GmbH Key Recent Developments

Mar 13,2017: FORMA Therapeutics Announces Achievement of First Clinical Development Milestone in Partnership with Boehringer Ingelheim

Mar 02,2017: Boehringer Ingelheim sponsors the new building of the Research Institute of Molecular Pathology in Vienna with EUR 52 million

Jan 23,2017: Inovalon Announces Agreement With Boehringer Ingelheim to Support Outcome-Based Contracting

Nov 30,2016: Boehringer Ingelheim Selects ACD/Labs for International Deployment

Oct 18,2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers

## Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors' business structure and strategies with GlobalData's detailed SWOT analysis. In this, the company's core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report's detailed insight into the company's strategic, business and operational performance.

**Note:** Some sections may be missing if data is unavailable for the company.

## Table of Content

### SECTION 1 - ABOUT THE COMPANY

Boehringer Ingelheim GmbH - Key Facts  
Boehringer Ingelheim GmbH - Key Employees  
Boehringer Ingelheim GmbH - Key Employee Biographies  
Boehringer Ingelheim GmbH - Major Products and Services  
Boehringer Ingelheim GmbH - Pharmaceutical Pipeline Products Data  
Boehringer Ingelheim GmbH, Pipeline Products by Therapy Area  
Boehringer Ingelheim GmbH, Pipeline Products by Development Phase  
Boehringer Ingelheim GmbH - History  
Boehringer Ingelheim GmbH - Company Statement  
Boehringer Ingelheim GmbH - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries

### SECTION 2 – COMPANY ANALYSIS

Boehringer Ingelheim GmbH - Business Description  
Boehringer Ingelheim GmbH - Corporate Strategy  
Boehringer Ingelheim GmbH - SWOT Analysis  
SWOT Analysis - Overview  
Boehringer Ingelheim GmbH - Strengths  
Boehringer Ingelheim GmbH - Weaknesses  
Boehringer Ingelheim GmbH - Opportunities  
Boehringer Ingelheim GmbH - Threats  
Boehringer Ingelheim GmbH - Key Competitors

### SECTION 3 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017  
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017

## Boehringer Ingelheim GmbH, Recent Deals Summary

### SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Mar 13, 2017: FORMA Therapeutics Announces Achievement of First Clinical Development Milestone in Partnership with Boehringer Ingelheim

Mar 02, 2017: Boehringer Ingelheim sponsors the new building of the Research Institute of Molecular Pathology in Vienna with EUR 52 million

Jan 23, 2017: Inovalon Announces Agreement With Boehringer Ingelheim to Support Outcome-Based Contracting

Nov 30, 2016: Boehringer Ingelheim Selects ACD/Labs for International Deployment

Oct 18, 2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers

Aug 03, 2016: Boehringer Ingelheim: Growth in all core businesses

Jul 20, 2016: The European Stroke Organisation and Boehringer Ingelheim launch the “Angels Initiative”, a unique healthcare initiative to improve acute stroke care across Europe

Jul 04, 2016: Gaia Novarino wins Boehringer Ingelheim’s FENS Award 2016 for Exceptional Research in Neuroscience

Jun 10, 2016: Simone Menne – new Member of the Board of Managing Directors of Boehringer Ingelheim/Responsible for Corporate Board Division Finance

May 23, 2016: Boehringer Ingelheim and BioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing

### SECTION 5 – APPENDIX

Methodology  
About GlobalData  
Contact Us  
Disclaimer

### LIST OF TABLES

Boehringer Ingelheim GmbH, Key Facts  
Boehringer Ingelheim GmbH, Key Employees  
Boehringer Ingelheim GmbH, Key Employee Biographies  
Boehringer Ingelheim GmbH, Major Products and Services  
Boehringer Ingelheim GmbH, Number of Pipeline Products by Therapy Area  
Boehringer Ingelheim GmbH, Number of Pipeline Products by Development Stage  
Boehringer Ingelheim GmbH, History  
Boehringer Ingelheim GmbH, Other Locations  
Boehringer Ingelheim GmbH, Subsidiaries  
Boehringer Ingelheim GmbH, Key Competitors  
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017  
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017  
Boehringer Ingelheim GmbH, Recent Deals Summary

### LIST OF FIGURES

Boehringer Ingelheim GmbH, Pipeline Products by Therapy Area  
Boehringer Ingelheim GmbH, Pipeline Products by Development Phase  
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017  
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

### COMPANIES MENTIONED

Phibro Animal Health Corp  
Pfizer Inc  
Novartis AG  
Jurgen Schmidt Chemievertretung GmbH  
F. Hoffmann-La Roche Ltd  
Eli Lilly and Company  
Bristol-Myers Squibb Company  
Bayer HealthCare AG

### I would like to order:

**Product name:** Boehringer Ingelheim GmbH - Strategic SWOT Analysis Review  
**Product link:** <https://marketpublishers.com/r/BFFC7371C30EN.html>  
**Product ID:** BFFC7371C30EN  
**Price:** US\$ 125.00 (Single User License / Electronic Delivery)

*If you want to order Corporate License or Hard Copy, please, contact our Customer Service: [office@marketpublishers.com](mailto:office@marketpublishers.com)*

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/BFFC7371C30EN.html>

### To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
E-mail:  
Company:  
Address:  
City:  
Zip/Post Code:  
Country:  
Tel:  
Fax:  
Your message:

\* All fields are required

Customer Signature \_\_\_\_\_

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at [https://marketpublishers.com/docs/terms\\_conditions.html](https://marketpublishers.com/docs/terms_conditions.html)

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**